Entrada Therapeutics Inc (NASDAQ: TRDA) open the trading on Thursday, with great promise as it jumped 9.61% to $8.78, before settling in for the price of $8.01 at the close. Taking a more long-term approach, TRDA posted a 52-week range of $4.93-$21.79.
Nevertheless, stock’s Earnings Per Share (EPS) this year is -303.81%. This publicly-traded company’s shares outstanding now amounts to $38.22 million, simultaneously with a float of $22.79 million. The organization now has a market capitalization sitting at $335.57 million. At the time of writing, stock’s 50-day Moving Average stood at $6.17, while the 200-day Moving Average is $7.89.
Entrada Therapeutics Inc (TRDA) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Entrada Therapeutics Inc’s current insider ownership accounts for 41.04%, in contrast to 51.12% institutional ownership. According to the most recent insider trade that took place on Nov 12 ’25, this organization’s 10% Owner bought 100,736 shares at the rate of 7.76, making the entire transaction reach 781,638 in total value, affecting insider ownership by 4,664,924. Preceding that transaction, on Nov 11 ’25, Company’s 10% Owner bought 46,434 for 7.50, making the whole transaction’s value amount to 348,193. This particular insider is now the holder of 4,572,549 in total.
Entrada Therapeutics Inc (TRDA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.88 per share during the current fiscal year. Entrada Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -303.81% and is forecasted to reach -4.13 in the upcoming year.
Entrada Therapeutics Inc (NASDAQ: TRDA) Trading Performance Indicators
Let’s observe the current performance indicators for Entrada Therapeutics Inc (TRDA). It’s Quick Ratio in the last reported quarter now stands at 14.08. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.45.
In the same vein, TRDA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.50, a figure that is expected to reach -0.98 in the next quarter, and analysts are predicting that it will be -4.13 at the market close of one year from today.
Technical Analysis of Entrada Therapeutics Inc (TRDA)
[Entrada Therapeutics Inc, TRDA] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 94.41% While, its Average True Range was 84.40.
Raw Stochastic average of Entrada Therapeutics Inc (TRDA) in the period of the previous 100 days is set at 91.78%, which indicates a major rise in contrast to 88.63% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.59 that was higher than 0.39 volatility it exhibited in the past 100-days period.
